Literature DB >> 22973418

Pain management in patients with inflammatory bowel disease: insights for the clinician.

Arvind Iyengar Srinath1, Chelsea Walter, Melissa C Newara, Eva M Szigethy.   

Abstract

Abdominal pain is a common symptom in patients with inflammatory bowel disease (IBD) and has a profound negative impact on patients' lives. There are growing data suggesting that pain is variably related to the degree of active inflammation. Given the multifactorial etiologies underlying the pain, the treatment of abdominal pain in the IBD population is best accomplished by individualized plans. This review covers four clinically relevant categories of abdominal pain in patients with IBD, namely, inflammation, surgical complications, bacterial overgrowth, and neurobiological processes and how pain management can be addressed in each of these cases. The role of genetic factors, psychological factors, and psychosocial stress in pain perception and treatment will also be addressed. Lastly, psychosocial, pharmacological, and procedural pain management techniques will be discussed. An extensive review of the existing literature reveals a paucity of data regarding pain management specific to IBD. In addition, there is growing consensus suggesting a spectrum between IBD and irritable bowel syndrome (IBS) symptoms. Thus, this review for adult and pediatric clinicians also incorporates the literature for the treatment of functional abdominal pain and the clinical consensus from IBD and IBS experts on pharmacological, behavioral, and procedural methods to treat abdominal pain in this population.

Entities:  

Keywords:  Crohn’s Disease; abdominal pain; inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); narcotic bowel syndrome; small intestinal bacterial overgrowth; ulcerative colitis; visceral hypersensitivity

Year:  2012        PMID: 22973418      PMCID: PMC3437534          DOI: 10.1177/1756283X12446158

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  128 in total

1.  Treatment of nonorganic recurrent abdominal pain: cognitive-behavioral family intervention.

Authors:  Marco Antônio Duarte; Francisco José Penna; Eugênio Marcos Goulart Andrade; Camila Silva Peres Cancela; Joaquim Caetano Aguirre Neto; Terezinha Facury Barbosa
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-07       Impact factor: 2.839

Review 2.  Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome.

Authors:  S Wilson; T Maddison; L Roberts; S Greenfield; S Singh
Journal:  Aliment Pharmacol Ther       Date:  2006-09-01       Impact factor: 8.171

3.  Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys.

Authors:  Esme Fuller-Thomson; Joanne Sulman
Journal:  Inflamm Bowel Dis       Date:  2006-08       Impact factor: 5.325

Review 4.  Acupuncture for treatment of irritable bowel syndrome.

Authors:  B Lim; E Manheimer; L Lao; E Ziea; J Wisniewski; J Liu; B Berman
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  Pain in chronic pancreatitis: the role of reorganization in the central nervous system.

Authors:  Georg Dimcevski; Saber A K Sami; Peter Funch-Jensen; Domenica Le Pera; Massimiliano Valeriani; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Gastroenterology       Date:  2007-01-25       Impact factor: 22.682

Review 6.  Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery.

Authors:  Charles P Taylor; Timothy Angelotti; Eric Fauman
Journal:  Epilepsy Res       Date:  2006-11-28       Impact factor: 3.045

7.  The narcotic bowel syndrome: clinical features, pathophysiology, and management.

Authors:  David M S Grunkemeier; Joseph E Cassara; Christine B Dalton; Douglas A Drossman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10       Impact factor: 11.382

8.  Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.

Authors:  L A Houghton; C Fell; P J Whorwell; I Jones; D P Sudworth; J D Gale
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

9.  Antidepressants and inflammatory bowel disease: a systematic review.

Authors:  Antonina A Mikocka-Walus; Deborah A Turnbull; Nicole T Moulding; Ian G Wilson; Jane M Andrews; Gerald J Holtmann
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-09-20

10.  "It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease.

Authors:  Antonina A Mikocka-Walus; Deborah A Turnbull; Nicole T Moulding; Ian G Wilson; Jane M Andrews; Gerald J Holtmann
Journal:  BMC Gastroenterol       Date:  2007-09-24       Impact factor: 3.067

View more
  38 in total

Review 1.  Mechanisms on spasmolytic and anti-inflammatory effects of a herbal medicinal product consisting of myrrh, chamomile flower, and coffee charcoal.

Authors:  Cica Vissiennon; Karl-Heinz Goos; Jürgen Arnhold; Karen Nieber
Journal:  Wien Med Wochenschr       Date:  2017-01-13

2.  Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.

Authors:  Mohamed Noureldin; Peter D R Higgins; Shail M Govani; Shirley Cohen-Mekelburg; Brooke C Kenney; Ryan W Stidham; Jennifer F Waljee; Akbar K Waljee
Journal:  Aliment Pharmacol Ther       Date:  2018-11-14       Impact factor: 8.171

3.  Predictors of abdominal pain in depressed pediatric inflammatory bowel disease patients.

Authors:  Arvind I Srinath; Alka Goyal; Lori A Zimmerman; Melissa C Newara; Margaret A Kirshner; Francis Nicole McCarthy; David Keljo; David Binion; Athos Bousvaros; David R DeMaso; Ada Youk; Eva M Szigethy
Journal:  Inflamm Bowel Dis       Date:  2014-08       Impact factor: 5.325

4.  Perceived Stress in Patients with Common Gastrointestinal Disorders: Associations with Quality of Life, Symptoms and Disease Management.

Authors:  Joel S Edman; Jeffrey M Greeson; Rhonda S Roberts; Adam B Kaufman; Donald I Abrams; Rowena J Dolor; Ruth Q Wolever
Journal:  Explore (NY)       Date:  2016-12-16       Impact factor: 1.775

5.  Pain Management in Patients With Inflammatory Bowel Disease.

Authors:  Eva Szigethy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-01

Review 6.  Opioid misuse in gastroenterology and non-opioid management of abdominal pain.

Authors:  Eva Szigethy; Mitchell Knisely; Douglas Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-15       Impact factor: 46.802

7.  Co-expression of μ and δ opioid receptors by mouse colonic nociceptors.

Authors:  Raquel Guerrero-Alba; Eduardo Emmanuel Valdez-Morales; Nestor Nivardo Jiménez-Vargas; Romke Bron; Daniel Poole; David Reed; Joel Castro; Melissa Campaniello; Patrick A Hughes; Stuart M Brierley; Nigel Bunnett; Alan E Lomax; Stephen Vanner
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

8.  Predictors of Chronic Opioid Use in Newly Diagnosed Crohn's Disease.

Authors:  Nathan J Pauly; Lamprinos Michailidis; Michael G Kindred; Deborah Flomenhoft; Michelle R Lofwall; Sharon L Walsh; Jeffery C Talbert; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

Review 9.  [Pain management in chronic pancreatitis and chronic inflammatory bowel diseases].

Authors:  J C Preiß; J C Hoffmann
Journal:  Schmerz       Date:  2014-06       Impact factor: 1.107

Review 10.  Pediatric inflammatory bowel disease and depression: treatment implications.

Authors:  Divya Keethy; Christine Mrakotsky; Eva Szigethy
Journal:  Curr Opin Pediatr       Date:  2014-10       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.